Michael Alrutz
General Counsel at CHIMERIX, INC.
Net worth: 118 115 $ as of 30/04/2024
Profile
Michael A.
Alrutz is currently the Secretary, Senior Vice President & General Counsel at Chimerix, Inc. He previously worked as the General Counsel at Trimeris, Inc. from 2002 to 2011.
He completed his undergraduate degree at the University of Pennsylvania, his graduate degree at Duke University School of Law, and his doctorate at the Sackler School of Graduate Biomedical Sciences.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
CHIMERIX, INC.
0.15% | 31/03/2024 | 132,564 ( 0.15% ) | 118 115 $ | 30/04/2024 |
Michael Alrutz active positions
| Companies | Position | Start |
|---|---|---|
| CHIMERIX, INC. | General Counsel | 01/06/2012 |
Former positions of Michael Alrutz
| Companies | Position | End |
|---|---|---|
Trimeris, Inc.
 Trimeris, Inc. Pharmaceuticals: MajorHealth Technology Trimeris, Inc. develops therapeutics for viral diseases. It is a biopharmaceutical company engaged in the discovery, development and commercialization of novel therapeutic agents for the treatment of viral disease. The core technology platform of fusion inhibition is based on blocking viral entry into host cells. The company was founded in 1993 and is headquartered in Durham, NC. | General Counsel | 04/11/2011 |
Training of Michael Alrutz
| University of Pennsylvania | Undergraduate Degree |
| Duke University School of Law | Graduate Degree |
| Sackler School of Graduate Biomedical Sciences | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| CHIMERIX, INC. | Health Technology |
| Private companies | 1 |
|---|---|
Trimeris, Inc.
Trimeris, Inc. Pharmaceuticals: MajorHealth Technology Trimeris, Inc. develops therapeutics for viral diseases. It is a biopharmaceutical company engaged in the discovery, development and commercialization of novel therapeutic agents for the treatment of viral disease. The core technology platform of fusion inhibition is based on blocking viral entry into host cells. The company was founded in 1993 and is headquartered in Durham, NC. | Health Technology |
- Stock Market
- Insiders
- Michael Alrutz
